Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity
Siân R. Kitcher, … , Guy P. Richardson, Corné J. Kros
Siân R. Kitcher, … , Guy P. Richardson, Corné J. Kros
Published August 8, 2019
Citation Information: JCI Insight. 2019;4(15):e126764. https://doi.org/10.1172/jci.insight.126764.
View: Text | PDF
Research Article Neuroscience Therapeutics

ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity

  • Text
  • PDF
Abstract

Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of sensory hair cells from the inner ear. ORC-13661 is a new drug that was derived from PROTO-1, a compound first identified as protective in a large-scale screen utilizing hair cells in the lateral line organs of zebrafish larvae. Here, we demonstrate, in zebrafish larvae and in mouse cochlear cultures, that ORC-13661 provides robust protection of hair cells against both ototoxins, the AGs and cisplatin. ORC-13661 also prevents both hearing loss in a dose-dependent manner in rats treated with amikacin and the loading of neomycin-Texas Red into lateral line hair cells. In addition, patch-clamp recordings in mouse cochlear cultures reveal that ORC-13661 is a high-affinity permeant blocker of the mechanoelectrical transducer (MET) channel in outer hair cells, suggesting that it may reduce the toxicity of AGs by directly competing for entry at the level of the MET channel and of cisplatin by a MET-dependent mechanism. ORC-13661 is therefore a promising and versatile protectant that reversibly blocks the hair cell MET channel and operates across multiple species and toxins.

Authors

Siân R. Kitcher, Nerissa K. Kirkwood, Esra D. Camci, Patricia Wu, Robin M. Gibson, Van A. Redila, Roberto Ogelman, Julian A. Simon, Edwin W. Rubel, David W. Raible, Guy P. Richardson, Corné J. Kros

×

Figure 3

ORC-13661 prevents hearing threshold shifts in amikacin-treated rats.

Options: View larger image (or click on image) Download as PowerPoint
ORC-13661 prevents hearing threshold shifts in amikacin-treated rats.
He...
Hearing threshold shifts in rats treated with a 10-day course of amikacin [320 mg/(kg.day); subcutaneous injection] with or without concurrent ORC-13661 [0.2, 1, 5 mg/(kg.day); oral administration]. Mean pretreatment to post-treatment shifts in hearing thresholds are reported; positive values indicate increasing levels of hearing loss. Amikacin treatment alone results in a substantial loss of hearing between 4 and 32 kHz; hearing threshold shifts in rats receiving 1 and 5 mg/(kg.day) of ORC-13661 were significantly reduced at 32 kHz (P < 0.05 and P < 0.01, respectively) compared with amikacin alone. Controls were treated with ORC-13661 or saline alone. The number of recordings for each condition was as follows: control, 16; amikacin, 19; ORC-13661 (0.2 mg/kg) + amikacin, 5; ORC-13661 (1 mg/kg) + amikacin, 8; ORC-13661 (5 mg/kg) + amikacin, 7. Within a condition n numbers are the same for each frequency tested. For statistical analysis 2-way ANOVA was used. Error bars represent SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts